Upsher-Smith Signs an Agreement with Dr. Reddy's Laboratories to Acquire its Two Neurology Products
Shots:
- Dr. Reddy’s to receive $70M upfront- $40.5M as milestones- an additional payment including existing contractual obligation and inventory with royalties on sales on a quarterly basis
- Upsher-Smith to get commercialization rights of Dr. Reddy’s Zembrace Symtouch (sumatriptan injection- 3mg) & Tosymra (sumatriptan nasal spray- 10 mg) in the US & other territories
- Zembrace and Tosymra (DFN-02) are commercialized by Promius Pharma- a subsidiary of Dr. Reddy’s- indicated for the patients with episodic migraine having no benefits with existing therapies
Ref: Dr. Reddy's | Image: Dr. Reddy's
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com